Gurgo A M, Massino Ferri F, Iulianella R, Luciani C, Lucifero A, Staropoli P, Rocchi M
Reparto di Cardiologia-UTIC Casa di Cura Nuova Itor Via di Pietralata, 162 00158 Roma.
Ital Heart J Suppl. 2001 Nov;2(11):1236-9.
We report the case of a 40-year-old HIV-positive man, undergoing three-drug antiretroviral therapy for 2 years that included a protease inhibitor (ritonavir). The patient was admitted to our Coronary Care Unit with an acute anterior myocardial infarction. He smoked 20 cigarettes/day and had a family history of hypertension. At the time of hospitalization, triglyceride levels were found to be high (290 mg/dl). Metabolic alterations associated with the prolonged use of protease inhibitors, such as insulin resistance, dyslipidemia and lipodystrophy, have recently been described. This side effect may lead to premature coronary artery disease. Therefore it is mandatory to be aware that treatment with protease inhibitors in HIV-positive patients, despite survival prolongation and lowering of AIDS complications, may accelerate atherosclerosis and precipitate acute coronary events, especially in patients with pre-existing cardiovascular risk factors.
我们报告了一名40岁的HIV阳性男性病例,该患者接受包含蛋白酶抑制剂(利托那韦)的三联抗逆转录病毒治疗已达2年。该患者因急性前壁心肌梗死入住我们的冠心病监护病房。他每天吸烟20支,有高血压家族史。住院时发现甘油三酯水平较高(290mg/dl)。最近已描述了与长期使用蛋白酶抑制剂相关的代谢改变,如胰岛素抵抗、血脂异常和脂肪代谢障碍。这种副作用可能导致冠状动脉疾病提前发生。因此,必须认识到,尽管蛋白酶抑制剂治疗可延长HIV阳性患者的生存期并降低艾滋病并发症,但可能会加速动脉粥样硬化并引发急性冠状动脉事件,尤其是在已有心血管危险因素的患者中。